Compare HAFC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | MYGN |
|---|---|---|
| Founded | 1982 | 1991 |
| Country | United States | United States |
| Employees | 610 | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.0M | 481.6M |
| IPO Year | 2000 | 1996 |
| Metric | HAFC | MYGN |
|---|---|---|
| Price | $25.39 | $4.81 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $31.33 | $8.06 |
| AVG Volume (30 Days) | 213.7K | ★ 1.3M |
| Earning Date | 04-27-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ 22.44 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | $270,165,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $18.65 | $7.19 |
| Revenue Next Year | $7.28 | $5.64 |
| P/E Ratio | $10.24 | ★ N/A |
| Revenue Growth | ★ 15.28 | 2.33 |
| 52 Week Low | $19.25 | $3.76 |
| 52 Week High | $30.20 | $11.44 |
| Indicator | HAFC | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 43.74 |
| Support Level | $24.38 | $3.93 |
| Resistance Level | $25.57 | $5.67 |
| Average True Range (ATR) | 0.84 | 0.39 |
| MACD | -0.11 | 0.11 |
| Stochastic Oscillator | 19.15 | 44.41 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.